Related Experiment Videos
Contemporary management of angina: part I. Risk assessment
D R Zanger1, A J Solomon, B J Gersh
1Georgetown University Medical Center, Washington, DC, USA.
Insights
Risk stratification for ischemic heart disease guides treatment decisions. Surgery benefits specific patient groups, while others receive optimal medical therapy including aspirin and lipid-lowering agents.
Area of Science:
- Cardiology
- Family Medicine
- Internal Medicine
Background:
- Ischemic heart disease (IHD) is a prevalent condition managed by family physicians.
- Effective risk stratification is crucial for identifying patients needing invasive treatments.
- Accurate assessment guides the choice between medical therapy, percutaneous revascularization, and surgical intervention.
Purpose of the Study:
- To outline the importance of risk stratification in ischemic heart disease management.
- To delineate patient groups who benefit from surgical revascularization versus medical therapy.
- To clarify the role of percutaneous revascularization in IHD treatment.
Main Methods:
- Review of clinical history and physical examination findings.
- Utilization of noninvasive diagnostic tests.
- Interpretation of angiography results for treatment planning.
Main Results:
- Coronary artery bypass surgery improves outcomes in patients with left ventricular dysfunction, left main coronary artery disease, or triple-vessel disease.
- Surgery is also beneficial for patients with proximal left anterior descending artery disease and significant ischemia.
- Medical therapy, including aspirin, beta-blockers, and lipid-lowering agents, is the definitive treatment for other patients.
Conclusions:
- Risk stratification is essential for optimizing ischemic heart disease treatment strategies.
- Surgical intervention is indicated for specific, well-defined patient populations with severe coronary artery disease.
- Percutaneous revascularization serves primarily as a palliative measure, not improving mortality compared to medical therapy.
Abstract:
Ischemic heart disease is one of the most common disorders managed by family physicians. Stratifying patients according to risk is important early in the course of the disease to identify patients who require invasive (percutaneous or surgical) treatment. Physical examination, clinical history, noninvasive tests and angiography are all helpful in determining who will benefit most from medical therapy, percutaneous revascularization or coronary artery bypass surgery. Surgery improves morbidity and mortality in a well-defined group of patients with left ventricular dysfunction and left main coronary artery disease or triple-vessel disease. Patients with proximal left anterior descending artery disease and moderate or severe ischemia benefit from surgery as well. In all other patients, definitive treatment includes aspirin, beta-adrenergic blockers and lipid-lowering agents. Percutaneous revascularization should be considered primarily a palliative measure, because it has never been shown to improve mortality more than medical therapy.